Skip to main content
Signal8

BioInvent International AB (publ) (BOVNF)

BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer. The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions. Its leading investigational compound is BI-1206, which is being developed to address both non-Hodgkin lymphoma and a range of solid tumors. Beyond this flagship program, BioInvent is advancing a diverse pipeline of therapeutic candidates. These include agents designed to target tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a vital role in regulating the immune system. The company's portfolio also features BT-001 for solid tumor indications, as well as BI-1808 and BI-1910 – both anti-TNFR2 antibodies specifically intended for the treatment of solid tumors and cutaneous T-cell lymphoma. To further its development initiatives, BioInvent has established several key collaborations. It maintains a strategic alliance with Pfizer Inc. for the development of antibodies targeting tumor-associated myeloid cells. The company also collaborates with Transgene to jointly create innovative multi-functional oncolytic viruses aimed at solid tumors. Additionally, a collaboration and supply agreement with Merck facilitates the clinical advancement of BI-1808. Founded in 1996, BioInvent International AB (publ) maintains its headquarters in Lund, Sweden.

Sector: Biotechnology

Industry: Biotechnology

BioInvent International AB (publ) logo

BioInvent International AB (publ)

OTC:BOVNFHealthcare
CLOSED
Mkt Cap-
EV-
Float47.51M
O/S65.8M
VOL650 sh
$ Vol$182
RVOL0.18×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsMar 4 · in 4mo
Dilution
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 47.51M · FMP free float

8.8K
Oct 30 (18d)prev 12▲ 72991.7%
9.65
Oct 30 (18d)prev 999.99▼ 99.0%
Borrow (IBKR)

The cost to borrow BOVNF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis8 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20268.8K sh
Oct 15, 202612 sh
Sep 30, 202612 sh
Sep 15, 202612 sh
Aug 31, 202612 sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume

Too few published sessions to show a reading in context.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for BOVNF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 8,771 BOVNF shares were sold short (0.02% of a 47.51M-share float, 9.65 days to cover).